医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Food and Drug

Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India

Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India

その他ヘルスヘルスケア製薬　 TimeLine: Administration Delegation from Food and Drug

2023年08月30日

Otsuka Medical Devices and Recor Medical Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension

Otsuka Medical Devices and Recor Medical Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension

ヘルスケア医療機器心臓学臨床試験　 TimeLine: Administration FDA Food and Drug

2023年08月23日

Otsuka Medical Devices and ReCor Medical Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration

Otsuka Medical Devices and ReCor Medical Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration

ヘルスケア医療機器臨床試験　 TimeLine: Administration Food and Drug Ultrasound Renal Denervation uRDN

2022年11月30日

Dr. Reddy’s Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

Dr. Reddy’s Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

バイオテクノロジーヘルスケア製薬　 TimeLine: Administration Food and Drug Reddy's Laboratories Announces Approval for Lenalidomide Capsules USFDA

2021年10月19日

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

バイオテクノロジーヘルスケアヘルス一般医療用品臨床試験製薬遺伝学　 TimeLine: Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound an Oral Orexin Agonist in Clinical Development for Narcolepsy Type Food and Drug NT1 TAK-994

2021年07月28日

SCC Soft Computer’s Blood Bank Product Receives 510(k) Clearance from the U.S. Food and Drug Administration

その他ヘルスヘルスケアヘルス一般医療用品医療管理　 TimeLine: Administration Food and Drug SCC Soft Computer’s Blood Bank Product Receives

2021年01月20日

AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo

AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo

バイオテクノロジーヘルスケア病院臨床試験製薬　 TimeLine: AVITA Medical Files Food and Drug IDE RECELL System Investigational Device Exemption

2020年06月02日

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA) Acceptance for Review of an NDA for the Combination Oral Hypomethylating Agent Cedazuridine and Decitabine (ASTX727 or oral C-DEC), for the Treatment of MDS and CMML

ヘルスケア腫瘍学臨床試験製薬　 TimeLine: Administration Astex Pharmaceuticals Announces ASTX727 or oral C-DEC FDA Food and Drug

2020年02月12日